ES2548228T3 - Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio - Google Patents
Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio Download PDFInfo
- Publication number
- ES2548228T3 ES2548228T3 ES13708908.2T ES13708908T ES2548228T3 ES 2548228 T3 ES2548228 T3 ES 2548228T3 ES 13708908 T ES13708908 T ES 13708908T ES 2548228 T3 ES2548228 T3 ES 2548228T3
- Authority
- ES
- Spain
- Prior art keywords
- benzimidazol
- compound
- amino
- tert
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594460P | 2012-02-03 | 2012-02-03 | |
| US201261594460P | 2012-02-03 | ||
| PCT/IB2013/050555 WO2013114250A1 (en) | 2012-02-03 | 2013-01-22 | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2548228T3 true ES2548228T3 (es) | 2015-10-15 |
Family
ID=47846092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13708908.2T Active ES2548228T3 (es) | 2012-02-03 | 2013-01-22 | Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8927587B2 (enExample) |
| EP (1) | EP2809655B1 (enExample) |
| JP (1) | JP6002785B2 (enExample) |
| AR (1) | AR089865A1 (enExample) |
| CA (1) | CA2861439C (enExample) |
| ES (1) | ES2548228T3 (enExample) |
| TW (1) | TW201341370A (enExample) |
| UY (1) | UY34602A (enExample) |
| WO (1) | WO2013114250A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2961403A4 (en) | 2013-03-01 | 2016-11-30 | Zalicus Pharmaceuticals Ltd | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL |
| KR102435145B1 (ko) | 2013-12-13 | 2022-08-24 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드의 프로드럭 |
| EP3110799A4 (en) * | 2014-02-27 | 2017-10-11 | Epirus Biopharmaceuticals, Inc. | Heterocyclic inhibitors of the sodium channel |
| EP3148992A1 (en) | 2014-05-30 | 2017-04-05 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
| WO2016009303A1 (en) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| CN107922350B (zh) * | 2015-09-11 | 2022-04-19 | 大日本住友制药株式会社 | 新的苯并咪唑化合物及其医药用途 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CA3063901A1 (en) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| JPWO2018212162A1 (ja) * | 2017-05-17 | 2020-03-19 | 株式会社トクヤマ | ジアミノベンゼン化合物の製造方法 |
| JP7277431B2 (ja) | 2017-07-11 | 2023-05-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのカルボキサミド |
| CA3088764A1 (en) * | 2018-01-15 | 2019-07-18 | UCB Biopharma SRL | Fused imidazole derivatives as il-17 modulators |
| EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| CN115397826B (zh) * | 2020-04-14 | 2025-07-15 | 宾夕法尼亚大学理事会 | 取代的{1,2,4,}三唑并{1,5-a}嘧啶化合物及其使微管稳定的应用 |
| WO2022108849A1 (en) * | 2020-11-17 | 2022-05-27 | Arisan Therapeutics Inc. | Heterocyclic compounds as therapeutic agents |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| KR20240031299A (ko) | 2021-06-04 | 2024-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법 |
| US20240294512A1 (en) | 2021-06-04 | 2024-09-05 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256702A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CN114249654B (zh) * | 2021-12-30 | 2023-11-14 | 江苏广域化学有限公司 | 烷基苯胺类化合物的制备方法 |
| CN116462662A (zh) | 2022-01-18 | 2023-07-21 | 成都康弘药业集团股份有限公司 | 芳香并环类Nav1.8抑制剂及其用途 |
| CN114288289A (zh) * | 2022-02-17 | 2022-04-08 | 昆山彭济凯丰生物科技有限公司 | 具有镇痛和/或止痒功能的药物组合物及其应用 |
| CR20240513A (es) | 2022-04-22 | 2025-04-30 | Vertex Pharma | Compuestos de heteroarilo para el tratamiento del dolor |
| CA3256604A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| US20250388543A1 (en) | 2022-04-22 | 2025-12-25 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| GEAP202516637A (en) | 2022-04-25 | 2025-03-25 | Siteone Therapeutics Inc | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
| CN120603815A (zh) | 2022-12-06 | 2025-09-05 | 沃泰克斯药物股份有限公司 | 钠通道的取代四氢呋喃调节剂的合成方法 |
| CN116621789A (zh) * | 2023-05-31 | 2023-08-22 | 上海吉奉生物科技有限公司 | 一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法 |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2425185A1 (en) * | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
| EA200500289A1 (ru) * | 2002-07-31 | 2005-06-30 | Еуро-Селтик С. А. | Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов |
| AU2004283751B2 (en) * | 2003-10-24 | 2011-05-19 | Exelixis, Inc. | p70S6 kinase modulators and method of use |
| WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| JP2009532381A (ja) * | 2006-03-31 | 2009-09-10 | アストラゼネカ アクチボラグ | 二環式ベンズイミダゾール化合物、および代謝型グルタミン酸受容体増強剤としての該化合物の使用 |
| SI2076508T1 (sl) | 2006-10-18 | 2011-04-29 | Pfizer Prod Inc | Spojine biaril eter sečnine |
| US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| WO2008118758A1 (en) | 2007-03-23 | 2008-10-02 | Icagen, Inc. | Inhibitors of ion channels |
| CA2685952C (en) | 2007-05-03 | 2012-03-13 | Pfizer Limited | N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| AP2516A (en) | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
| JP5460589B2 (ja) | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| WO2009079011A1 (en) * | 2007-12-19 | 2009-06-25 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| EP2072516A1 (en) * | 2007-12-21 | 2009-06-24 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists |
| US8628695B2 (en) | 2008-04-18 | 2014-01-14 | E I Du Pont De Nemours And Company | Surface-modified ruthenium oxide conductive material, lead-free glass(es), thick film resistor paste(s), and devices made therefrom |
| EP2364089B1 (en) * | 2008-10-30 | 2016-12-07 | Biogen MA Inc. | Heterobicyclic sphingosine 1-phosphate analogs |
| JP5667934B2 (ja) * | 2010-06-28 | 2015-02-12 | 大日本住友製薬株式会社 | 新規２環性複素環化合物からなる医薬 |
| WO2012116440A1 (en) | 2011-03-03 | 2012-09-07 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
-
2013
- 2013-01-22 ES ES13708908.2T patent/ES2548228T3/es active Active
- 2013-01-22 EP EP13708908.2A patent/EP2809655B1/en not_active Not-in-force
- 2013-01-22 JP JP2014555351A patent/JP6002785B2/ja not_active Expired - Fee Related
- 2013-01-22 CA CA2861439A patent/CA2861439C/en not_active Expired - Fee Related
- 2013-01-22 WO PCT/IB2013/050555 patent/WO2013114250A1/en not_active Ceased
- 2013-01-29 US US13/752,571 patent/US8927587B2/en not_active Expired - Fee Related
- 2013-01-30 TW TW102103504A patent/TW201341370A/zh unknown
- 2013-01-31 UY UY0001034602A patent/UY34602A/es not_active Application Discontinuation
- 2013-02-01 AR ARP130100299A patent/AR089865A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6002785B2 (ja) | 2016-10-05 |
| TW201341370A (zh) | 2013-10-16 |
| UY34602A (es) | 2013-09-30 |
| CA2861439C (en) | 2016-07-12 |
| US20130274243A1 (en) | 2013-10-17 |
| EP2809655A1 (en) | 2014-12-10 |
| CA2861439A1 (en) | 2013-08-08 |
| JP2015509110A (ja) | 2015-03-26 |
| US8927587B2 (en) | 2015-01-06 |
| WO2013114250A1 (en) | 2013-08-08 |
| AR089865A1 (es) | 2014-09-24 |
| EP2809655B1 (en) | 2015-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2548228T3 (es) | Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio | |
| ES2526541T3 (es) | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje | |
| CN103906746B (zh) | 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 | |
| ES2532356T3 (es) | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje | |
| ES2526675T3 (es) | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje | |
| ES2525581T3 (es) | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje | |
| ES2526981T3 (es) | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje | |
| ES2398606T3 (es) | Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio | |
| ES2532357T3 (es) | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor | |
| JP6067031B2 (ja) | Ｎ−アミノスルホニルベンズアミド | |
| JP6058023B2 (ja) | スルホンアミド誘導体 | |
| ES2533065T3 (es) | Bencenosulfonamidas útiles como inhibidores de los canales de sodio | |
| ES2371932T3 (es) | Derivados de pirazina como moduladores de los canales de sodio para el tratamiento del dolor. | |
| CN103958481A (zh) | 可用于治疗的哒嗪衍生物 | |
| ES2382876T3 (es) | Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1 | |
| ES2331153T3 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
| JP2016540811A (ja) | Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤 | |
| JP2009523842A (ja) | ナトリウムチャネルモジュレーターとしてのピリジン誘導体 | |
| ES2526982T3 (es) | N-Sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje | |
| HK1198650B (en) | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | |
| HK1107812A (en) | Pyridine derivatives |